Condition: Solid Tumor · Sponsor: RemeGen Co., Ltd.
The primary objective of Phase I of this trial is to evaluate the safety, tolerability, maximum tolerated dose (MTD)/maximum administered dose (MAD) of RC148 in patients with locally advanced unresectable or metastatic solid tumors to determine the recommended Phase II dose (RP2D), and the secondary objective is to evaluate the PK and PD characteristics, immunogenicity and preliminary clinical efficacy of RC148. Phase II will primarily evaluate the efficacy of the RC148 combination regimen, and secondarily will assess safety and tolerability, PK characteristics, and immunogenicity. During the trial, investigators will also evaluate the potential correlation of biomarkers with efficacy.
This description comes directly from the study's public registry record.
Jianming Fang, ph.D · +8610-58075763 · jianmingfang@hotmail.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Anhui, China | Recruiting |
| Beijing Tiantan Hospital, Capital Medical University | Beijing, China | Recruiting |
| Beijing University Cancer Hospital | Beijing, China | Recruiting |
| The Fifth Medical Center of Chinese PLA General Hospital | Beijing, China | Recruiting |
| Jilin Cancer Hospital | Changchun, China | Recruiting |
| Hunan Cancer Hospital | Changsha, China | Recruiting |
| Hunan Second People's Hospital | Changsha, China | Recruiting |
| Sichuan Cancer Hospital | Chengdu, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, China | Recruiting |
| The Second Affiliated Hospital of Guilin Medical University | Guilin, China | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06016062